Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filedfiledCritical
Priority to ECSP961876priorityCriticalpatent/ECSP961876A/en
Publication of ECSP961876ApublicationCriticalpatent/ECSP961876A/en
Pharmaceuticals Containing Other Organic And Inorganic Compounds
(AREA)
Abstract
El invento proporciona una forma de dosificación farmacéutica adaptada para la administración en el tracto gastrointestinal de un paciente que comprende darifenacina, o una de sus sales farmacéuticamente aceptable y un adyuvante diluyente o vehículo farmacéuticamente aceptable caracterizada porque la forma de dosificación está adaptada para liberar al menos el 10% en peso de la darifenacina o de su sal farmacéuticamente aceptable, en el tracto gastrointestinal inferior del paciente. La formulación minimiza los efectos secundarios indeseados y aumenta la biodisponibilidad de la darifenacina.The invention provides a pharmaceutical dosage form adapted for administration to the gastrointestinal tract of a patient comprising darifenacin, or a pharmaceutically acceptable salt thereof and a diluting adjuvant or pharmaceutically acceptable carrier characterized in that the dosage form is adapted to release at least 10% by weight of darifenacin or its pharmaceutically acceptable salt, in the patient's lower gastrointestinal tract. The formulation minimizes unwanted side effects and increases the bioavailability of darifenacin.
LACTAMA COMPOUND (N) - ((S) -2-HIDROXI-3-METHYLBUTIRILE) -1- (L-ALANINIL) - (S) -1-AMINO-3-METHYL-4,5,6,7-TETRAHYDRO -2H-3-BENZAZEPIN-2-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, PROCEDURE FOR THE INHIBITION OF THE B-AMYLOID PEPTIDE RELEASE AND / OR ITS SYNTHESIS THAT USES IT AND ITS USE FOR THE FABR
A PHARMACEUTICAL COMPOSITION THAT INCLUDES NATEGLINIDA, A PROCESS FOR ITS PREPARATION AND THE USE OF SUCH COMPOSITION FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF METABOLIC DISORDERS, ESPECIALLY DIABETES, OR A DISEASE OR CONDITION ASSOCIATED WITH DIABETY.
1ALFA, 26 DIHIDROXI-D-HOMO-VITAMIN D3, A PHARMACEUTICAL COMPOSITION THAT INCLUDES IT, A PROCEDURE FOR ITS PREPARATION AND USE OF THEM IN THE ELABORATION OF A MEDICINAL PRODUCT
DERIVATIVE OF NAFTIRIDIN-DIBENZO [A, D] CICLOHEPTENO-10-ACETICO, PHARMACEUTICAL COMPOSITION, AND THE USE OF THAT DERIVATIVE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT.
A BENZAMIDE COMPOUND, A MEDICINAL PRODUCT CONTAINING IT, AND USE FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF A DIGESTIVE DISEASE OR TO IMPROVE THE MOBILITY OF THE GASTROINTESTINAL TRACT.
Method of using 2- (4- (4-chlorophenyl) cyclohexyl) -3-hydroxy-1,4-naphthoquinone for cancer treatment (USE OF 2- (4- (4-CHLOROPHENYL) CYCLOHEXYL)- 3-HYDROXY-1,4-NAPHTHOQUINONE FOR THE TREATMENT OF CANCER)